Time-dependent changes in the effects of cholinesterase inhibitors on shuttle-box avoidance

Effects of low doses of physostigmine on avoidance learning and EEG in two strains of mice

The effects of the cholinomimetic drug, physostigmine (0, 0.01, 0.025, 0.05 and 0.1 mg/kg, i.p.), on shuttle-box avoidance learning and electroencephalographic (EEG) activity were investigated, in two separate studies, in mice belonging to the inbred C57BL/6 (C57) and DBA/2 (DBA) strains. The results of the behavioral investigation showed a consistent, significant enhancement of avoidance performance, on the whole of 5 daily training sessions, in C57 mice treated with the lowest dose (0.01 mg/kg) and in DBA mice treated with the highest doses (0.05 and 0.1 mg/kg) of the drug. Doses higher than 0.01 mg/kg, in C57 mice, and lower than 0.05 mg/kg, in DBA mice, had no significant effect. The avoidance improvements induced by physostigmine cannot be ascribed to general behavioral activation, since the doses that increased avoidance responses did not affect or even depressed spontaneous locomotor activity. The same doses of treatment which increased avoidance responding, also induced, in the same strains, consistent enhancement of 4-7 Hz (theta) EEG band power and decrease of 7-12 Hz (alpha) band power. Results suggest that the effects induced by physostigmine on the EEG and on the shuttle-box performance of mice are related to the same neurochemical systems, and are dependent upon the interaction of the dose with specific strain sensitivity.

Effects of oxiracetam, physostigmine, and their combination on active and passive avoidance learning in mice

The nootropic drug oxiracetam (50 and 100 mg/kg) had no effect on one-trial passive avoidance acquisition in CD-1 mice, while the acetylcholinesterase inhibitor physostigmine improved passive avoidance performance at doses of 0.025 and 0.05 mg/kg given either pre- or posttraining. In a multitrial avoidance task (shuttle-box), a consistent tendency to better performance was displayed by mice receiving oxiracetam (50 and 100 mg/kg) or physostigmine (0.01 and 0.025 mg/kg, but not 0.05 mg/kg). Combinations of the two drugs never improved active or passive avoidance performance more than drugs given separately. This indicates no advantage in combining nootropics and anticholinesterase inhibitors to improve learning and memory.

A vasopressin metabolite produces qualitatively different effects on memory retrieval depending on the accessibility of the memory

A vasopressin metabolite, AVP4-9, was injected 1 h prior to retention tests at 1, 6, 11, and 16 days after learning to test the hypothesis that the peptide exerts qualitatively different effects on memory retrieval depending on the accessibility of the memory. The findings provided strong support for this hypothesis: At a retention interval associated with excellent recall in control animals, pretest administration of AVP4-9 (3.0 micrograms/kg) significantly impaired memory, while this same treatment significantly improved recall at an interval associated with poor retention in controls. At retention tests associated with intermediate recall in controls, retrieval was not significantly affected by the peptide treatment. This pattern of results indicates that the peptide treatment is interacting with endogenous changes that correspond to the accessibility of the memory.

Behavioural plasticity and the cholinergic system

Evidence for the involvement of the cholinergic system in behavioural plasticity is reviewed by considering three forms of behavioural plasticity: habituation, learning and memory, and tolerance development. Although the cholinergic system may modulate the response tendencies of an animal, it does not appear to be involved in the process of habituation. A number of studies have indicated that the cholinergic system may be involved in learning and memory processes in infrahuman animals. In general, cholinergic antagonists tend to disrupt memory while agonists may, under the appropriate conditions, facilitate memory. Recent studies have pointed to a relation between dysfunctions of the cholinergic system and dysfunctions of memory in aged animals. Studies of tolerance development suggest that the cholinergic system may undergo plastic changes which may underlie the development of tolerance to some drugs, with receptor alterations being the most reproducible finding. However, more work is necessary to establish the degree of plasticity. The cholinergic system also appears to be involved in learning and memory processes in humans. However, attempts to correct the memory deficits in aged humans by manipulating the cholinergic system have met with limited success. The reasons for this lack of success are briefly considered.